Literature DB >> 23795786

Causes of death in men with prostate cancer: an analysis of 50,000 men from the Thames Cancer Registry.

Simon Chowdhury1, David Robinson, Declan Cahill, Alejo Rodriguez-Vida, Lars Holmberg, Henrik Møller.   

Abstract

OBJECTIVE: To investigate causes of death in a UK cohort of patients with prostate cancer. PATIENTS AND METHODS: We examined causes of death in a UK cohort of 50,066 men with prostate cancer diagnosed between 1997 and 2006 reported to the Thames Cancer Registry (TCR) and followed-up to the end of 2007. The underlying cause of death was taken from the death certificate. Uptake of PSA screening was low in the UK during the period studied. We examined the relationship between cause of death and patient characteristics at diagnosis including age, cancer stage, and treatment (≤6 months of diagnosis).
RESULTS: In all, 20,181 deaths occurred during the period; 49.8% recorded as being due to prostate cancer, 17·8% to cardiovascular disease, 11·6% to other cancers, and 20·7% to other causes. Irrespective of age, cancer stage, or treatment ≤6 months of diagnosis, prostate cancer was an important cause of death ranging from 31·6% to 74·3% of all deaths in different subgroups.
CONCLUSION: For men with prostate cancer diagnosed in a setting where uptake of PSA screening is low, our findings challenge the belief that prostate cancer is not an important cause of death.
© 2013 BJU International.

Entities:  

Mesh:

Year:  2013        PMID: 23795786     DOI: 10.1111/bju.12212

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  8 in total

1.  A co-clinical platform to accelerate cancer treatment optimization.

Authors:  Andrea Lunardi; Pier Paolo Pandolfi
Journal:  Trends Mol Med       Date:  2014-11-17       Impact factor: 11.951

2.  UPDATE - Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies.

Authors:  Andrea Kokorovic; Alan I So; Hosam Serag; Christopher French; Robert J Hamilton; Jason P Izard; Jasmir G Nayak; Frédéric Pouliot; Fred Saad; Bobby Shayegan; Armen Aprikian; Ricardo A Rendon
Journal:  Can Urol Assoc J       Date:  2022-08       Impact factor: 2.052

3.  Cardiovascular risk of gonadotropin-releasing hormone antagonist versus agonist in men with prostate cancer: an observational study in Taiwan.

Authors:  Yu-Hsuan Joni Shao; Jian-Hua Hong; Chun-Kai Chen; Chao-Yuan Huang
Journal:  Prostate Cancer Prostatic Dis       Date:  2022-06-03       Impact factor: 5.455

4.  Causes of Death after Prostate Cancer Diagnosis: A Population-Based Study.

Authors:  Yadong Guo; Xiaohui Dong; Shiyu Mao; Fuhan Yang; Ruiliang Wang; Wenchao Ma; Ji Liu; Cheng Li; Zongtai Zheng; Wentao Zhang; Aihong Zhang; Xudong Yao
Journal:  Oxid Med Cell Longev       Date:  2022-04-23       Impact factor: 7.310

5.  Extended follow-up for prostate cancer incidence and mortality among participants in the Prostate, Lung, Colorectal and Ovarian randomized cancer screening trial.

Authors:  Paul F Pinsky; Eric Miller; Philip Prorok; Robert Grubb; E David Crawford; Gerald Andriole
Journal:  BJU Int       Date:  2018-11-02       Impact factor: 5.588

6.  Association of Health-Care System With Prostate Cancer-Specific Mortality in African American and Non-Hispanic White Men.

Authors:  Daniella Klebaner; P Travis Courtney; Isla P Garraway; John Einck; Abhishek Kumar; Maria Elena Martinez; Rana McKay; James D Murphy; Humberto Parada; Ajay Sandhu; Tyler Stewart; Kosj Yamoah; Brent S Rose
Journal:  J Natl Cancer Inst       Date:  2021-10-01       Impact factor: 11.816

7.  Evaluating variation in use of definitive therapy and risk-adjusted prostate cancer mortality in England and the USA.

Authors:  Ashwin Sachdeva; Jan H van der Meulen; Mark Emberton; Paul J Cathcart
Journal:  BMJ Open       Date:  2015-02-24       Impact factor: 2.692

8.  Causes of death in men with localized prostate cancer: a nationwide, population-based study.

Authors:  Mieke Van Hemelrijck; Yasin Folkvaljon; Jan Adolfsson; Olof Akre; Lars Holmberg; Hans Garmo; Pär Stattin
Journal:  BJU Int       Date:  2015-05-15       Impact factor: 5.588

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.